Since the onset of the COVID-19 pandemic, researchers have tried to find the most effective and safe treatment modality for the disease. These treatment strategies have changed over time in accordance with new evidence gathered from several clinical trials and public health records. To provide a framework for the treatment of COVID-19, the Infectious Diseases Society of America (IDSA) recently released a set of updated guidelines for the management of COVID-19 consisting of 32 recommendations based on the latest evidence available. We are publishing a series of articles to cover these guidelines.
This article focuses on guidelines for the use of Remdesivir for the treatment of COVID-19. Recommendations: Remdesivir can be initiated within the first seven days of the onset of symptoms in patients with mild-to-moderate COVID-19 who are at risk of progression of the disease. Recommended…
